Physical properties and solubility studies of Nifedipine-PEG 1450/HPMCAS-HF solid dispersions

References

• Ali SL. 1989. Nifedipine. In: Florey K, editor. Analytical profiles of drug substances. New York: Academic Press.
   Google Scholar
• Bley H, Fussnegger B, Bodmeier R. 2010. Characterization and stability of solid dispersions based on PEG/polymer blends. Int J Pharm. 390:165–173.
   PubMed Web of Science ®Google Scholar
• Boje KM, Sak M, Fung H-L. 1988. Complexation of nifedipine with substituted phenolic ligands. Pharm Res. 5:655–659.
   PubMed Web of Science ®Google Scholar
• Cilurzo F, Selmin F, Minghetti P, Gennari CGM, Demartin F, Montanari L. 2008. Characterization and physical stability of fast-dissolving microparticles containing nifedipine. Eur J Pharm Biopharm. 68:579–588.
   PubMed Web of Science ®Google Scholar
• Friedrich H, Nada A, Bodmeier R. 2005. Solid state and dissolution rate characterization of co-ground mixtures of nifedipine and hydrophilic carriers. Drug Dev Ind Pharm. 31:719–728.
   PubMed Web of Science ®Google Scholar
• Frydrych M, Roman S, Green NH, MacNeil S, Chen B. 2015. Thermoresponsive, stretchable, biodegradable and biocompatible poly(glycerol sebacate)-based polyurethane hydrogels. Polym Chem. 6:7974–7987.
   Web of Science ®Google Scholar
• Grooff D, De Villiers MM, Liebenberg W. 2007. Thermal methods for evaluating polymorphic transitions in nifedipine. Thermochim Acta. 454:33–42.
   Web of Science ®Google Scholar
• Gupte A, DeHart M, Stagner WC, Haware RV. 2017. Comparative binder efficiency modeling of dry granulation binders using roller compaction. Drug Dev Ind Pharm. 43:574–583.
   PubMed Web of Science ®Google Scholar
• Hancock BC, Zografi G. 1997. Characteristics and significance of the amorphous state in pharmaceutical systems. J Pharm Sci. 86:1–12.
   PubMed Web of Science ®Google Scholar
• Haware RV, Kancharla JP, Udupa AK, Staton S, Gupta MR, Al-Achi A, Stagner WC. 2015. Physico-mechanical properties of coprocessed excipient MicroceLac® 100 by DM3 approach. Pharm Res. 32:3618–3635.
   PubMed Web of Science ®Google Scholar
• Iqbal WS, Chan KL. 2015. FTIR spectroscopic study of poly(ethylene glycol)-nifedipine dispersion stability in different relative humidities. J Pharm Sci. 104:280–284.
   PubMed Web of Science ®Google Scholar
• Kesisoglou F, Panmai S, Wu Y. 2007. Nanosizing-oral formulation development and biopharmaceutical evaluation. Adv Drug Deliv Rev. 59:631–644.
   PubMed Web of Science ®Google Scholar
• Kestur US, Taylor LS. 2010. Role of polymer chemistry in influencing crystal growth rates from amorphous felodipine. Cryst Eng Comm. 12:2390–2397.
   Web of Science ®Google Scholar
• Konno H, Taylor LS. 2006. Influence of different polymers on the crystallization tendency of molecularly dispersed amorphous felodipine. J Pharm Sci. 95:2692–2705.
   PubMed Web of Science ®Google Scholar
• Konno H, Taylor LS. 2008. Ability of different polymers to inhibit the crystallization of amorphous felodipine in the presence of moisture. Pharm Res. 25:969–978.
   PubMed Web of Science ®Google Scholar
• Kothari K, Ragoonanan V, Suryanarayanan R. 2015. The role of drug-polymer hydrogen bonding interactions on the molecular mobility and physical stability of nifedipine solid dispersions. Mol Pharm. 12:162–170.
   PubMed Web of Science ®Google Scholar
• Nie B, Stutzman J, Xie A. 2005. A vibrational spectral maker for probing the hydrogen-bonding status of protonated Asp and Glu residues. Biophys J. 88:2833–2847.
   PubMed Web of Science ®Google Scholar
• Nunes C, Mahendrasingam A, Suryanarayanan R. 2005. Quantification of crystallinity in substantially amorphous materials by synchrotron X-ray powder diffractometry. Pharm Res.. 22:1942–1953.
   PubMed Web of Science ®Google Scholar
• Serajuddin ATM. 1999. Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. J Pharm Sci. 88:1058–1066.
   PubMed Web of Science ®Google Scholar
• Shah B, Kakumanu VK, Bansal AK. 2006. Analytical techniques for quantification of amorphous/crystalline phases in pharmaceutical solids. J Pharm Sci. 95:1641–1665.
   PubMed Web of Science ®Google Scholar
• Stroyer A, McGinity JW, Leopold CS. 2006. Solid state interactions between the proton pump inhibitor omeprazole and various enteric coating polymers. J Pharm Sci. 95:1342–1353.
   PubMed Web of Science ®Google Scholar
• Tanno F, Nishiyama Y, Kokubo H, Obara S. 2004. Evaluation of hypromellose acetate succinate (HPMCAS) as a carrier in solid dispersions. Drug Dev Ind Pharm. 30:9–17.
   PubMed Web of Science ®Google Scholar
• Tsume Y, Mudie DM, Langguth P, Amidon GE, Amidon GL. 2014. The biopharmaceutics classification system: subclasses for in vivo predictive dissolution (IPD) methodology and IVIVC. Eur J Pharm Sci. 57:152–163.
   PubMed Web of Science ®Google Scholar
• Ueda K, Higashi K, Yamamoto K, Moribe K. 2013. Inhibitory effect of hydroxypropyl methylcellulose acetate succinate on drug recrystallization from a supersaturated solution assessed using nuclear magnetic resonance measurements. Mol Pharm. 10:3801–3811.
   PubMed Web of Science ®Google Scholar
• USP. 2017. Validation of Compendial Procedures USP 40-NF 35 Online <1225>. The United States Pharmacopeial Convention; 1780–1786.
   Google Scholar
• Vasconcelos T, Sarmento B, Costa P. 2007. Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs. Drug Discov Today. 12:1068–1075.
   PubMed Web of Science ®Google Scholar
• Vo CL-N, Park C, Lee B-J. 2013. Current trends and future perspectives of solid dispersions containing poorly water-soluble drugs. Eur J Pharm Biopharm. 85:799–813.
   PubMed Web of Science ®Google Scholar
• Zajc N, Obreza A, Bele M, Srčič S. 2005. Physical properties and dissolution behaviour of nifedipine/mannitol solid dispersions prepared by hot melt method. Int J Pharm. 291:51–58.
   PubMed Web of Science ®Google Scholar